EVs to drive lithium-ion battery demand growth by remarkable 48% CAGR through 2030
The demand for lithium-ion battery is expected to reach 115 GWh by 2030 with consumer electronics growth projected at 3 per cent, stationary storage at 14 per cent, and EVs at a remarkable 48 per cent CAGR between now and 2030.
As per the report, this growth will also be supported by India's commitments to Net-Zero goals and favorable government policies on catalysing demand for low-carbon energy, cell manufacturing, and end-of-life (EoL) management of lithium-ion batteries.
On the flip side, with rise in this demand, India also faces challenges such as a rising import bill and environmental impact due to disposal of end-of-life lithium-ion batteries.
"India currently lacks Li-ion cell pack manufacturing capabilities and mining infrastructure, making it heavily reliant on imports of LiBs consisting of critical battery-active materials such as Lithium, Cobalt, Nickel, and Manganese," the ICEA report read.
The projected cumulative demand for the period 2024 to 2030 for these critical active materials is estimated to reach more than 250kT, translating into an import exposure of more than USD 5 billion.
To address these challenges, the government has introduced various policy interventions, such as the Critical Minerals Mission, trade duty exemptions on critical minerals, among others.
Further, CPCB introduced the Battery Waste Management Rules (BWMR) in 2022, establishing a regulatory framework to foster recycling and retention of critical battery-active materials within India.
Nearly 39 per cent of consumer electronics batteries that have reached their end-of-life do not get collected.
At COP26 held in 2021, India committed to an ambitious five-part "Panchamrit" pledge. They included reaching 500 GW of non-fossil electricity capacity, generating half of all energy requirements from renewables, and reducing emissions by 1 billion tonnes by 2030.
India as a whole also aims to reduce the emissions intensity of GDP by 45 per cent. Finally, India commits to net-zero emissions by 2070.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
17 minutes ago
- Mint
Retail participation in capital mkt increases; demat accounts surge to 19.4-cr in 2025
Mumbai, The Indian market is witnessing remarkable participation from retail investors, with a surge in demat accounts to 19.4 crore in 2025 from 3.6 crore in 2019, a senior Sebi official said on Tuesday. Meanwhile, domestic institutional ownership in listed companies has increased from 13 per cent to 20 per cent, while foreign ownership has declined from 22 per cent to 17 per cent. Speaking at an event organised by IVCA Renewable Energy Summit 2025, Ruchi Chojer, Executive Director at Sebi, said that trust is the cornerstone of investment, and India has earned that trust. "At Sebi, our regulatory approach has focused on balancing capital formation with systemic stability and investor protection. Trust is the cornerstone of investment, and India has earned that trust," she was quoted in a statement issued by IVCA. She shared that retail participation has surged from 3.6 crore demat accounts in 2019 to 19.4 crore in 2025. Highlighting the evolution of capital markets in the country, Chojer said that over the last three decades, India's capital markets have transformed into one of the world's top 10 equity ecosystems resilient, inclusive, and increasingly driven by domestic participation. In the last 10 years alone, Indian companies have raised nearly ₹ 93 lakh crore through equity and debt, with FY 2024–25 witnessing a record ₹ 4.3 lakh crore in equity issuance, including ₹ 1.7 lakh crore via IPOs. "This growth is powered not just by policy and infrastructure, but by deepening investor trust," she said. Additionally, she spoke on the importance of capital markets in India's clean energy journey. "As India undertakes its green transition, the role of capital markets and particularly alternative investment funds will be critical. Financing long-gestation sectors like grid modernisation, storage, and transmission requires patient and risk-tolerant capital. Sebi has already enabled blended finance structures, allowing philanthropic and multilateral capital to invest through junior units in AIFs. This is a vital step in unlocking capital for the energy transition," she said. Also, she stressed that India's clean energy transition cannot be driven by listed companies alone and AIFs must play a key role in driving ESG adoption among unlisted investee companies, especially as 40 per cent of AIF capital comes from foreign investors who expect alignment with global disclosure standards. "We are open to proposals for ESG-labelled AIF categories, and we believe well-structured tax incentives can further catalyse investment into sectors with long-term impact and higher risk profiles," she said. Looking to the future, she noted, "India will need an estimated USD 250 billion by 2030 to finance renewable energy, storage, and transmission. Sebi remains committed to enabling this transformation by providing regulatory clarity, reducing policy risk, and supporting innovative investment structures. Our goal is to ensure that India's capital markets continue to serve not just as engines of growth, but also as platforms for building a sustainable, future-ready economy.' This article was generated from an automated news agency feed without modifications to text.
Business Standard
19 minutes ago
- Business Standard
Zydus Lifesciences gets USFDA Nod for Celecoxib Capsules
Zydus Lifesciences announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib Capsules, marking another addition to its growing U.S. generics portfolio. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body. It is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain. It is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old. Celecoxib capsules will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. According to IQVIA MAT data (May 2025), Celecoxib Capsules recorded annual sales of approximately USD 122.6 million in the U.S. market. With this approval, Zydus has now secured a total of 428 final approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since it began its U.S. regulatory filing process in FY 200304. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. The counter shed 0.14% to Rs 967.15 on the BSE.
Time of India
32 minutes ago
- Time of India
Govt not to allow sale of biostimulants without scientific nod: Agriculture Minister Shivaraj Singh Chouhan
Agriculture Minister Shivaraj Singh Chouhan is concerned about biostimulant quality. The government will now require scientific approval for biostimulant sales. This decision follows farmer complaints about product ineffectiveness. The ministry will create standard operating procedures. Action will be taken against suspicious manufacturers. India's biostimulant market is projected to grow significantly by 2032. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Concerned over irregularities in the biostimulant market, Agriculture Minister Shivaraj Singh Chouhan on Tuesday said the government will not allow the sale of such products without scientific a review meeting, Chouhan pulled up the ministry and ICAR officials for watching with closed eyes the rising sale of biostimulants amid farmers' complaints about their quality and minister directed his ministry officials to permit the sale of those biostimulants which are effective in the farm field and meet the quality parameters, according to an official also directed ministry officials to prepare a standard of procedure (SOP) by setting rules and regulations."Now, permission will be given only after it is scientifically approved and the entire responsibility for this will be with the concerned officials," he are substances or microorganisms (such as beneficial bacteria, fungi, or plant extracts) that, when applied to seeds, plants, or soil, stimulate natural plant concern over irregularities in the sector, Chouhan said biostimulants have been sold in the country for many years and the permission period for the sale is being extended one year after another, but many times complaints come from the field that there is no benefit from it, still it is being sold."It is necessary to review biostimulants thoroughly to see how much benefit the farmers are getting from it; if not, then permission to sell it cannot be given," Chouhan of companies started selling biostimulants without any rules, but the government will not let this happen at any cost, he government will take action against suspicious manufacturers of biostimulants, he there is a comprehensive regulatory framework for biostimulants through amendments to the Fertiliser (In organic , Organic or Mixed) (Control) Order, 1985 (FCO), with recent updates in 2024 and biostimulants market in India was valued at approximately USD 355-362 million in 2024 and is projected to reach between USD 1.13 billion and USD 1.2 billion by 2032.
